Τίτλος:
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: To assess the prognostic and predictive significance of HER-1/EGFR protein levels in high-risk patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy. Methods: 595 high-risk breast cancer patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF). Disease-free survival (DFS) was the primary end point. HER-1/EGFR was assessed by immunohistochemistry (IHC) in 312 patients. Results: HER-1/EGFR expression was detected in 54 of 312 patients (17%). Positive expression of HER-1/EGFR was significantly associated with negative receptor status (52 vs. 17%, p < 0.001), worse histological grade (70 vs. 45%, p = 0.001), HER-2 overexpression (46 vs. 27%, p = 0.01) and positive p53 expression (48 vs. 19%, p < 0.001). With a median follow-up of 7 years, the total number of relapses was 105 (34%), and the total number of deaths 69 (22%). The analysis for DFS provides significant evidence that the HER-1/EGFR effect on the risk of disease progression was different according to treatment (interaction p = 0.02). Regarding overall survival, a trend towards a significant difference for an interaction of HER-1/EGFR and treatment was found (p = 0.07). Conclusion: The present study demonstrated a differential effect of positive HER-1/EGFR expression in the two treatment groups, with HER-1/EGFR being a negative prognostic marker in the absence of paclitaxel. Copyright © 2008 S. Karger AG.
Συγγραφείς:
Tzaida, O.
Gogas, H.
Dafni, U.
Kyroudi, A.
Papaspyrou, I.
Kyriakou, V.
Malamou-Mitsi, V.
Alamani, M.
Skopa, C.
Kostopoulos, I.
Kastritis, E.
Pectasides, D.
Briasoulis, E.
Kalofonos, H.P.
Aravantinos, G.
Fountzilas, G.
Arapantoni-Dadioti, P.
Περιοδικό:
DIAGNOSTIC ONCOLOGY
Λέξεις-κλειδιά:
antineoplastic agent; cyclophosphamide; epidermal growth factor receptor; epidermal growth factor receptor 2; epirubicin; fluorouracil; methotrexate; paclitaxel; protein p53; tamoxifen, adult; aged; article; breast cancer; cancer chemotherapy; cancer growth; cancer risk; clinical evaluation; clinical trial; controlled clinical trial; controlled study; disease free survival; female; high risk patient; human; immunohistochemistry; major clinical study; multiple cycle treatment; priority journal; prognosis; protein expression; protein protein interaction; randomized controlled trial; treatment outcome, Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Genes, erbB-1; Humans; Immunohistochemistry; Methotrexate; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis
